INDSWFTLABNSEInd-Swift Laboratories Limited· PharmaceuticalsMediumNeutral
Announced Fri, 25 Jul · 18:16 IST

Disclosure under Regulation 30 of the SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015

Fii Holding Above 10pctOwnership Changes View source PDF

INDSWFTLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Mauritius-based HCP Investments has acquired 44,85,124 equity shares of Ind-Swift Laboratories by converting equivalent warrants into equity shares. This preferential allotment raised HCP's stake in the company from 4.49% to 10.36% of paid-up share capital. The shares were allotted on 21 July 2025, and the company's total equity share capital expanded to Rs. 72.38 crore (7.24 crore shares of Rs. 10 each). HCP Investments is not part of the promoter/promoter group of the company.

Likely market impact

A non-promoter foreign investor crossing the 10% ownership mark signals meaningful institutional confidence in the company, which is generally viewed positively. Existing shareholders should note potential further dilution, as the total diluted share capital could expand to 8.51 crore shares if all outstanding warrants are converted.